vindesine / Generic mfg. - LARVOL DELTA

Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial. (PubMed, JAMA Oncol) - P2 | "Dasatinib was administered with a 2-week vindesine and dexamethasone regimen as induction, followed by sequential CD19 and CD22 CAR T-cell therapies and single-agent dasatinib maintenance. The primary end point was CMR rate after CD19 CAR T-cell therapy...Further studies with larger cohorts and longer follow-up durations are needed. ClinicalTrials.gov Identifier: NCT04788472."

Clinical • Journal • Acute Lymphocytic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • CD22

Frontline Systemic Therapeutic Patterns and Outcomes in Rosai-Dorfman Disease: A Multicenter Retrospective Analysis (SOHO 2026) - " Of 44 patients, 27 received targeted therapy (cobimetinib, n = 26; trametinib, n = 1) and 17 received fixedduration chemotherapy (methotrexate, n = 7; cladribine/cytarabine, n = 5; vinblastine/vindesine, n = 3; cyclophosphamide, n = 2). Both chemotherapy and targeted therapy demonstrated clinically meaningful ORR and PFS. Although small sample size prevented statistical comparison, a greater proportion of targeted therapy patients required next-line therapy, reflecting higher discontinuation rates from AEs. While preliminary data suggest both treatment approaches may be effective, larger studies would provide more definitive insights."

Retrospective data • Oncology • BRAF • DNMT3A • KRAS • MAP2K1 • MAP2K2 • NRAS

Olverembatinib-Based Treatment for Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Multi-Center Retrospective Study (SOHO 2026) - "Blinatumomab was applied for consolidation in 9 of 18 patients (50%). Nine of 18 (50%) patients have entered the maintenance therapy phase, of whom 6 received olverembatinib only, 2 received a combination of olverembatinib and chemotherapy, and 1 received a combination of dasatinib and chemotherapy due to financial issues... Olverembatinib-based regimen with lower-intensity chemotherapy showed promising outcomes with acceptable side effects as frontline therapy in patients with Ph+ ALL, warranting further trials to investigate better strategies. ALL: acute lymphoblastic leukemia, allo-HSCT: allogeneic hematopoietic stem cell transplantation, BCR::ABL1: breakpoint cluster region–Abelson murine leukemia viral oncogene homolog 1 fusion, CAR-T: chimeric antigen receptor T-cell, CMR: complete molecular remission, CR: complete response, IKZF1: Ikaros family zinc finger protein 1, PCR: polymerase chain reaction, Ph+: Philadelphia chromosome–positive, TKI: tyrosine kinase..."

Retrospective data • Acute Lymphocytic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR • IKZF1

CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P2 | N=197 | Recruiting | Sponsor: The First Affiliated Hospital of Soochow University | Not yet recruiting ➔ Recruiting | Trial primary completion date: Aug 2025 ➔ Aug 2027

Enrollment open • Trial primary completion date • Non-Hodgkin’s Lymphoma

Identification of Repurposed Drugs Against Monkeypox Virus Through Comprehensive Virtual Screening. (PubMed, Biotechnol J) - "The MD and convolutional neural-network (GNINA) scoring analyses converged on vindesine for DNA topoisomerase and LY2090314 for DNA polymerase. Importantly, the workflow was applied to targets with distinct prior information, including a structurally characterized DNA polymerase supported by homologue inhibitor data and a less-characterized DNA topoisomerase requiring homology modelling. These results illustrate an adaptable repurposing pipeline for prioritizing therapeutic candidates against emerging infectious diseases, although experimental validation remains required."

Journal • Preclinical • Infectious Disease

Long-term outcomes of vindesine or vincristine substitutions for vinblastine in classical Hodgkin lymphoma. (PubMed, Chin Med J (Engl)) - No abstract available

Journal • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Adult T-cell Leukemia/Lymphoma in Japan: Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs. (PubMed, J Health Econ Outcomes Res) - "Mogamulizumab was most frequently utilized (60.4%), as monotherapy or in combination regimens...Additionally, use of combinations such as VCAP-AMP-VECP, which include vincristine, cyclophosphamide, doxorubicin, and prednisone; adriamycin, manimustine, and prednisone; and vindesine, etoposide, carboplatin, and prednisone, was observed in 33.3% of patients...Although real-world studies based on MDV database have certain limitations, the findings of this study provide deeper understanding of the real-world patient characteristics, treatment patterns, HRU, and costs of ATL patients in Japan. The results indicate that patients often encounter high treatment costs and frequent hospitalizations, demonstrating the necessity for advanced regimens and highlighting the unmet need for more effective therapies in ATL patients that may reduce HRU and economic burden in this patient population."

HEOR • Journal • Real-world evidence • Adult T-Cell Leukemia-Lymphoma • Cardiovascular • Congestive Heart Failure • Diabetes • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hematological Malignancies • Leukemia • Lymphoma • Metabolic Disorders • Non-Hodgkin’s Lymphoma • Oncology • Peptic Ulcer • Transplantation

A Phase Ib Dose-Finding and Safety Study of Lisaftoclax Combined with a Pediatric-Inspired Chemotherapy Regimen in Adult Acute Lymphoblastic Leukemia (ALL) (ChiCTR) - P1 | N=30 | Not yet recruiting | Sponsor: The First Hospital of China Medical University; The First Hospital of China Medical University

New P1 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • T Acute Lymphoblastic Leukemia

EFFICACY AND SAFETY OF LIPOSOMAL MITOXANTRONE–CONTAINING REGIMENS IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED ADVANCED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (EHA 2026) - "The CMOP regimen consisted of cyclophosphamide 500–750 mg/m² intravenously on day 1, liposomal mitoxantrone 12–18 mg/m² intravenously on day 1, vindesine 3 mg intravenously on day 1, and methylprednisolone 80 mg intravenously on days 1–5. In anthracycline-based regimens (CHOP or CHOP-like), doxorubicin 35–50 mg/m² or epirubicin 45–70 mg/m² was administered intravenously on day 1 instead of liposomal mitoxantrone, while the doses of cyclophosphamide, vindesine, and methylprednisolone were consistent with those used in the CMOP regimen...Summary/Conclusion In elderly patients with advanced AITL, CMOP regimens containing liposomal mitoxantrone were associated with higher response rates and significantly prolonged survival without an apparent increase in major toxicities. These findings suggest that liposomal mitoxantrone–containing regimens may represent an effective and tolerable therapeutic option for elderly patients with advanced disease."

Clinical • Metastases • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • T Cell Non-Hodgkin Lymphoma

Alkaloids mediated regulation of microRNA in cancer: molecular insights and emerging therapeutic strategies. (PubMed, Front Oncol) - "Numerous anticancer drugs derived from alkaloids, including vindesine, vinblastine, vincristine, and vinorelbine, have been developed and are widely used in cancer therapeutics. We highlight how miRNAs function as key regulators and mediators of the anticancer mechanisms of these natural compounds. Furthermore, we have also summarized the potent role of different types of miRNAs in cancer progression and development."

Journal • Review • Oncology

ORELABRUTINIB PLUS R-CHOP FOR THE TREATMENT OF NEWLY DIAGNOSED NON-GCB DOUBLE-EXPRESSOR DIFFUSE LARGE B-CELL LYMPHOMA: A MULTICENTER, SINGLE-ARM, PHASE II STUDY (EHA 2026) - "Methods All eligible patients received 6-8 cycles of 21-day treatment, including O 150 mg once daily on days 1-14 combined with R-CHOP (rituximab 375 mg/m 2 on day 0; cyclophosphamide 750 mg/m 2 on day 1; doxorubicin 50 mg/m 2 on day 1; vindesine 4 mg on day 1; prednisone 100 mg on days 1-5). According to the LymphGen algorithm, the MCD-like subtype was the most prevalent (51.5%), followed by BN2-like (27.3%) and EZB-like (6.1%) subtypes; no significant differences in EFS were observed among genetic subgroups. . Summary/Conclusion In previously untreated non-GCB DE-DLBCL patients, O-RCHOP achieved promising efficacy with a manageable safety profile, supporting its promise as a feasible first-line regimen."

Clinical • IO biomarker • P2 data • Atrial Fibrillation • B Cell Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • BCL2 • CD79B • MYC • MYD88 • PIM1 • TP53

Comparison of the efficacy of vindesine and leurocristine for pediatric acute lymphoblastic leukemia and their effects on quality of life. (PubMed, Arch Med Sci) - "Group A showed no significant difference in the total efficacy rate and 5-year overall survival after treatment (p > 0.05) and had lower medical expenses, length of hospital stay, IL-6 and TNF-α expression, and total incidence of adverse reactions and higher KPS scores than group B (p < 0.05). Although no significant difference was observed between vindesine and leurocristine in treating pediatric acute lymphoblastic leukemia, patients administered vindesine had fewer adverse reactions, shorter length of hospital stay, lower medical expenses, and higher quality of life than those administered leurocristine, indicating a potential association with decreased serum IL-6 and TNF-α expression."

HEOR • Journal • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Pediatrics • Thrombocytopenia • IL6 • TNFA

OLVEREMBATINIB AS FRONTLINE TREATMENT FOR ADULT NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (EHA 2026) - "Clinical trials demonstrate that ponatinib-based regimens—whether combined with H-CVAD chemotherapy or blinatumomab—are highly effective in newly diagnosed Ph + ALL, eliciting sustained complete molecular response (CMR) rates of 84% and 87%, respectively, and translating into impressive overall survival (OS) (6-year OS 75% and 3-year OS 91%)...Induction regimens included olverembatinib combined with vindesine and prednisone (VP) (n=7), blinatumomab (n=4), or prednisone alone (n=1) Results Patients achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi) within 28 days...Non-hematologic adverse events were mostly grade 1-2, with no treatment-related pancreatitis, hypertension, cardiac arrhythmias, or vascular thrombotic events observed . Summary/Conclusion The olverembatinib-based combination regimen demonstrates high molecular response rates and promising short-term survival with a manageable safety profile in newly diagnosed Ph + ALL, offering a..."

Clinical • IO biomarker • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Hypertension • Neutropenia • Pancreatitis • Thrombocytopenia • ABL1

Novel Fusion Gene Transcripts and Targetable Mutations in High-Risk B-ALL With Exceptional Response to Venetoclax-Based Therapy. (PubMed, Genes Chromosomes Cancer) - "The patient received induction therapy with a modified COP regimen (cyclophosphamide, vindesine, dexamethasone) combined with the BCL2 inhibitor venetoclax, achieving a rapid and sustained complete remission. This case suggests that integrating deep genomic analysis can help identify potentially actionable therapeutic targets and provides preliminary clinical evidence supporting the efficacy of modified COP plus venetoclax in high-risk B-ALL with similar molecular features, highlighting a promising precision medicine strategy."

IO biomarker • Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • ARID1B • BCL6 • CREBBP • GRIK2 • MAN1A1

Primary Langerhans Cell Histiocytosis of the Maxilla: Case Report. (PubMed, Ear Nose Throat J) - "Postoperative chemotherapy with vincristine or vindesine was administered. This case underscores the importance of considering Langerhans cell histiocytosis in pediatric patients with refractory facial swelling and destructive bone lesions, and highlights the value of combined surgical and chemotherapeutic management."

Journal • Langerhans Cell Histiocytosis • Pediatrics • CD1a • CD68

LBL 2018: International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma (clinicaltrials.gov) - P3 | N=683 | Recruiting | Sponsor: University Hospital Muenster | Trial completion date: Nov 2027 ➔ Apr 2030 | Trial primary completion date: Nov 2027 ➔ Apr 2030

Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Oncology

FLOW: Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P2 | N=101 | Recruiting | Sponsor: The First Affiliated Hospital of Soochow University

New P2 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD19

Network-based discovery of tumor-checkpoint inverter drugs targeting pancreatic ductal adenocarcinoma cell states and macrophage reprogramming (AACR 2026) - "Cross-model validation identified state-specific candidate drugs, including Leuprolide, Vinblastine, and Mercaptopurine for GLS; Vindesine, Gossypol, and Binimetinib for MOS; and AT9283, Crizotinib, and Afatinib for PLS. Predicted MR-inversion scores correlated with experimental dose-response profiles in cell lines selected via OncoMatch.Together, these results establish a mechanistic link between tumor-intrinsic transcriptional states and macrophage immunosuppression, while identifying mutation-agnostic, state-specific drugs capable of reprogramming both tumor and immune compartments. This work provides a generalizable framework for network-based drug repurposing to overcome transcriptional plasticity and immune resistance in PDAC."

Oncology • Pancreatic Ductal Adenocarcinoma • APOE

Rux-cALL-Pol 2020: Single-arm interventional study with ruxolitinib and AIEOP-BFM 2017 Poland or AIEOP-BFM 2017 standard of care chemotherapy in children with acute lymphoblastic leukemia and confirmed activation of JAK/STAT pathway. (clinicaltrialsregister.eu) - P2/3 | N=25 | Recruiting | Sponsor: Medical University Of Lodz | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • AFF1 • CRLF2 • ETV6 • IKZF1 • JAK2 • KMT2A • PBX1 • RUNX1 • TCF3

Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: Children's Cancer Group, China | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial primary completion date • Hematological Malignancies • Lymphoma • Oncology

IntReALL BCP 2020 International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 (clinicaltrialsregister.eu) - P2/3 | N=765 | Not yet recruiting | Sponsor: Charite Universitaetsmedizin Berlin KR

New P2/3 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD22

Born with two faces: sequential DLBCL, NOS and TFHL-AI with TET2 mutation - a case report. (PubMed, Front Immunol) - "He achieved complete remission following six cycles of R-CHOP chemotherapy (rituximab, cyclophosphamide, vindesine, liposomal doxorubicin, and dexamethasone)...He received four cycles of the histone deacetylase inhibitor (HDACi) chidamide combined with COEP chemotherapy (cyclophosphamide, vindesine, etoposide, and prednisone), resulting in a partial remission...Although the prognosis is generally poor, treatment combining HDAC inhibitors such as chidamide with chemotherapy may offer therapeutic potential. Further studies are needed to clarify the molecular mechanisms underlying such lymphoid evolution and to guide optimal management."

Journal • B Cell Lymphoma • Dermatology • Developmental Disorders • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Otorhinolaryngology • Pruritus • TET2

Prospective, single-arm, multicenter clinical study of rituximab combined with cyclophosphamide, mitoxantrone liposomes, vincristine, and prednisone (R-CMOP) regimen in the treatment of previously untreated diffuse large B-cell lymphoma in patients aged 60 years or older or with underlying heart disease (ChiCTR) - P=N/A | N=72 | Not yet recruiting | Sponsor: The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital of Zhejiang University School of Medicine

New trial • B Cell Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Heart Failure • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Case Report: Vincristine-induced acute pancreatitis in pediatric Wilms tumor: first reported case challenging previous risk classifications and proposing vigilant monitoring protocols. (PubMed, Front Pediatr) - "Vincristine, a cornerstone vinca alkaloid in pediatric oncology, has historically been regarded as a low-risk agent for drug-induced acute pancreatitis (DIAP). Vindesine may serve as a safe and effective alternative agent. These findings underscore the importance of updating pediatric chemotherapy safety guidelines for vinca alkaloid-containing regimens."

Journal • Immunology • Nephrology • Oncology • Pain • Pancreatic Cancer • Pancreatitis • Pediatrics • Solid Tumor • Wilms Tumor • CEP72

Integrative Transcriptomic and Perturbagen Analyses Reveal Sex-Specific Molecular Signatures Across Glioma Subtypes. (PubMed, Cancers (Basel)) - "Perturbagen analysis nominated signature-reversing compounds across sexes, including histone deacetylase inhibitors, Aurora kinase inhibitors, microtubule-targeting agents such as vindesine, and multi-kinase inhibitors targeting VEGFR, PDGFR, FLT3, PI3K, and MTOR. Glioma grade comparisons reveal a shared neuronal-synaptic program accompanied by sex-specific transcriptional remodeling. These findings support sex-aware therapeutic strategies that pair modulation of neuron-glioma coupling with chromatin- or receptor tyrosine kinase/angiogenic-targeted agents, and they nominate biomarkers such as GLI1, MYOD1, GCGR, PRLHR, and HIST1H2BH for near-term validation."

Journal • Brain Cancer • Glioblastoma • Glioma • High Grade Glioma • Oncology • Solid Tumor • CHRNA7 • FLT3 • GLI1 • GRIN2A • GRIN2B • HOXA9 • MYOD1 • PLA2G2A • SAA1